Treatment of a spastic increase of muscle tone in multiple sclerosis with botulinum toxin

Close metadata

Recommended articles:

Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):86-96

A case of COVID-associated encephalopathy in a patient with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):159-163

A role of cerebrovascular diseases in the progression of multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):53-57

Questionnaires for arm function assessment in patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):36-42

Features of primary forms of headache in multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):70-73

Neurofilament light chain: a diagnostic potential for multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):115-119

Biobanking in clinical trials involving multiple sclerosis patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7-2):7-15

Optical coherence tomography angiography in the diagnosis of multiple sclerosis. Russian Annals of Ophthalmology. 2024;(2):63-70

Intrathecal baclofen therapy: a 30-year experience. Burdenko's Journal of Neurosurgery. 2024;(3):96-102

Optical coherence tomography in the diagnosis of multiple sclerosis. Russian Annals of Ophthalmology. 2024;(3):59-68

The article presents data of the reviews, consensus and recommendations on the use of botulinum toxin type A (BTA) in multiple sclerosis (MS) patients with spasticity syndrome. It presents the results of randomized clinical trials that confirm the efficacy and favorable safety profile of dysport in treatment of MS patients. The complex approach to spasticity therapy and rehabilitation in MS is discussed.

Keywords:

multiple sclerosis

symptomatic therapy

spasticity

botulinum toxin

Authors:

Kostenko E.V.

Poliklinika vosstanovitel'nogo lecheniia #7;
Kafedra nevrologii i neĭrokhirurgii Rossiĭskogo gosudarstvennogo meditsinskogo universiteta;
Kafedra nevrologii Moskovskogo gosudarstvennogo mediko-stomatologicheskogo universiteta

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Scopus AuthorID: 57224826008
ORCID: 0000-0001-6476-6417

List of references:

Gusev EI, Zavalishin IA, Boyko AN, Zacharova MN. Demyelinating diseases of the central nervous system. In Neurology (National reccomendations, 2^nd edition). Ed. by Gusev EI, Konovalov AN, Skvortsova VI. V. 1. M.: GEOTAR-Media; 2018. (In Russ.)
Boiko AN, Kukel’ TM, Lysenko MA, Vdovichenko TV, Gusev EI. Clinical epidemiology of multiple sclerosis in Moscow. Descriptive epidemiology in population of one region of Moscow. Zh nevrologii i psikhiatrii im. S.S. Korsakova. 2013;10(2):8-14. (In Russ.)
Kobelt G, Thompson A, Gannedahl M, Gannedahl M, Eriksson J; MSCOI Study Group; European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23(8):1123-1136. https://doi.org/10.1177/1352458517694432
Boyko A, Kobelt G, Berg J, Boyko O, Popova E, Capsa D, Eriksson J, The European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe: Results for Russia. Mult Sler. 2017;23(2)155-165. https://doi.org/10.1177/1352458517708668
Boyko A, Kesselring J, Paty DW, Siva A, Singhal B, Thompson A, Willoughby E. Multiple sclerosis and public health. Educational and management implications. World Health Organization, Department of Mental Health, Neuroscience and Neurological Disorders. 1999;2:1-11.
Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004;10(5):589-595.
Pozzilli C. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice. Expert Rev Neurother. 2013;13(12):49-54. https://doi.org/10.1586/14737175.2013.865877
Zwibel HL. Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv Ther. 2009;26(12):1043-1057. https://doi.org/10.1007/s12325-009-0082-x
Cheung J, Rancourt A, Di Poce S, Levine A, Hoang J, Ismail F, Boulias C, Phadke CP. Patient-identified factors that influence spasticity in people with stroke and multiple sclerosis receiving botulinum toxin injection treatments. Physiotherapy Can. 2015;67(2);157-166. https://doi.org/10.3138/ptc.2014-07
Hemmett L, Holmes J, Barnes M, Russell N. What drives quality of life in multiple sclerosis? QJM. 2004;97(10):671-676.
Gusev EI, Boyko AN, Kostenko EV. Spasticity: clinic, diagnostic and complex rehabilitation with botulintoxin. M.: GEOTAR-Media; 2017. (In Russ.)
Local damage of the brain in adults: spasticity syndrome. Pod red. Khat'kovoi EM.: MEDpress-inform; 2017. (In Russ.)
Gracies JM, Brashear A, Jech R, McAllister P, Banach M, Valkovic P, Walker H, Marciniak C, Deltombe T, Skoromets A, Khatkova S, Edgley S, Gul F, Catus F, De Fer BB, Vilain C, Picaut P; International Abobotulinumtoxin A Adult Upper Limb Spasticity Study Group. Safety and efficacy of abobotulinumtoxin A for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomized controlled trial. Lancet Neurol. 2015;14(10):992-1001. https://doi.org/10.1016/S1474-4422(15)00216-1
Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, Armstrong MJ, Gloss D, Potrebic S, Jankovic J, Karp BP, Naumann M, So YT, Yablon SA Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(19):1818-1826. https://doi.org/10.1212/WNL.0000000000002560
Gracies JM, Esquenazi A, Brashear A, Banach M, Kocer S, Jech R, Khatkova S, Benetin J, Vecchio M, McAllister P, Ilkowski J, Ochudlo S, Catus F, Grandoulier AS, Vilain C, Picaut P; International AbobotulinumtoxinA Adult Lower Limb Spasticity Study Group. Efficacy and safety of abobotulinumtoxin A in spastic lower limb: Randomized trial and extension. Neurology. 2017;89(22):2245-2253. https://doi.org/10.1212/WNL.0000000000004687
Cameron MH, Bethoux F, Davis N, Frederick M. Botulinum toxin for symptomatic therapy in multiple sclerosis Curr Neurol Neurosci Rep. 2014;14(8):463. https://doi.org/10.1007/s11910-014-0463-7
Kostenko EV, Batisheva TT, Riabukchina OV, Petrova LV, Boyko AN. Current wat of treatment of spastic muscle tonus with botulin toxin. M.: Real-taim; 2011. (In Russ.)
Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B, Poewe W, Wissel J, Bain P, Glickman S, Sayer A, Richardson A, Dott C. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry. 2000;68:707-712.
Habeka M, Karni A, Balash Y, Gurevich T. The place of the botulinum toxin in the management of multiple sclerosis. Clin Neurol Neurosurg. 2010;112:592-596. https://doi.org/10.1016/j.clineuro.2010.04.010
Gusev YI, Banach M, Simonow A, Skoromets A, Czlonkowska A, Shmidt T, Bojakowski J, Fryze W, Haase J, Judith Haas, Nowicki J, Johann Hagenah, Hans W. Kölmel, Christian Neumann & Sofia L Timirbaeva. Efficacy and safety of botulinum type a toxin in adductor spasticity due to multiple sclerosis. J Musculoskeletal Pain. 2008;16(3):175-188. https://doi.org/10.1080/10582450802161952
Otero-Romero S, Sastre-Garriga J, Comi G, Hartung HP, SoelbergSørensen P, Thompson AJ, Vermersch P, Gold R, Montalban X. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Mult Scler. 2016;22(11):1386-1396. https://doi.org/10.1177/1352458516643600
Dressler D, Bhidayasiri R, Bohlega S, Chahidi A, Chung TM, Ebke M, Jacinto LJ, Kaji R, Koçer S, Kanovsky P, Micheli F, Orlova O, Paus S, Pirtosek Z, Relja M, Rosales RL, Sagástegui-Rodríguez JA, Schoenle PW, Shahidi GA, Timerbaeva S, Walter U, Saberi FABotulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force. J Neurol. 2016;264(1):112-120. https://doi.org/10.1007/s00415-016-8304-z
Gold R, Oreja-Guevara C. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines. Expert Rev Neurother. 2013;13(12):55-59. https://doi.org/10.1586/14737175.2013.865880
Safarpour Y, Mousavi T, Jabbari B. Botulinum toxin treatment in multiple sclerosis, a review. Curr Treat Options Neurol. 2017;19(10):33. https://doi.org/10.1007/s11940-017-0470-5

Close metadata